HGH Fragment 5mg/vial 1 Vial by Bio-Peptide

Usage

1. Allow the sealed vial to reach room temperature before handling to minimise thermal shock to the lyophilised peptide.
2. Using an insulin syringe, draw 1–2 ml of bacteriostatic water and inject it slowly down the inner wall of the vial — never directly onto the powder cake.
3. Swirl the vial gently in a circular motion until fully dissolved; do not vortex or shake, as mechanical agitation degrades peptide bonds.
4. Calculate your dose volume: if 1 ml of bacteriostatic water was added to 5 mg, each 0.05 ml (50 µl) equals 250 mcg.
5. Inject subcutaneously into the abdominal region or another low-fat subcutaneous site using a 29–31 gauge insulin syringe, in a fasted metabolic state to maximise lipolytic synergy.
6. Store the reconstituted vial upright at 2–8 °C; label with the date of reconstitution and discard after 28 days or if any cloudiness or particulate matter appears.

Warnings

Frequently asked questions

Why does HGH Fragment 176-191 only target fat and not cause growth effects?

Fragment 176-191 lacks the N-terminal binding domain of full HGH that engages the GH receptor and triggers IGF-1 production. Without that receptor interaction, no anabolic or growth-promoting cascade is activated. The retained C-terminal sequence binds preferentially to fat-cell receptors governing lipolysis, confining biological activity strictly to adipose tissue mobilisation.

Does IGF-1 rise when using HGH Fragment 176-191?

No — serum IGF-1 remains unaffected during Fragment 176-191 administration. Because the peptide cannot bind the primary GH receptor site that signals the liver to produce IGF-1, the hepatic IGF-1 secretion pathway is never activated. This is one of the most clinically relevant distinctions between the fragment and full-length growth hormone therapy.

When is the optimal time to inject HGH Fragment 176-191 for maximum fat-burning effect?

Research protocols favour administration in a fasted state — typically first thing in the morning or 30 minutes before a training session — when circulating insulin is at its lowest. Low insulin levels remove the primary inhibitor of lipolysis, allowing Fragment 176-191 to engage adipocyte beta-3 adrenergic receptors with minimal interference and maximise free fatty acid release into circulation.

How do you reconstitute and store HGH Fragment 176-191 5mg after opening?

Add 1–2 ml of bacteriostatic water slowly down the side of the vial — never shake; swirl gently until the lyophilised powder dissolves completely. Once reconstituted, refrigerate at 2–8 °C and use within 28 days. Draw doses with an insulin syringe (29–31 gauge) for subcutaneous injection. Discard any vial showing particulate matter or discolouration.

Is post-cycle therapy required after a HGH Fragment 176-191 research cycle?

No standard PCT protocol is required. Fragment 176-191 exerts no androgenic, oestrogenic, or pituitary-suppressive activity; it does not engage the hypothalamic-pituitary-gonadal axis. Endogenous GH pulsatility and sex hormone levels are unaffected, so the hormonal recovery framework applied to anabolic steroids or SARM cycles is not applicable to this peptide. (2) angle_used

Manufacturer

Bio-Peptide's standing in the European research peptide sector is built on a principle its founders embedded into commercial operations from day one: the right to market a compound was conditional on an independent laboratory — not an internal QC team — certifying both the peptide's sequence identity and its endotoxin safety before a single vial shipped. That two-step external verification framework — HPLC confirmation of molecular sequence and purity percentage, paired with LAL (Limulus Amebocyte Lysate) endotoxin screening — has never been treated as an optional enhancement; it is a non-negotiable production gate applied to every batch, including HGH Fragment (176-191). Manufacturing infrastructure operates in alignment with cGMP standards, ensuring that documentation, environmental controls, and raw-material sourcing meet the same benchmarks applied to pharmaceutical-adjacent production environments. The result is a traceable chain from amino-acid procurement through lyophilisation and final vial release — each step auditable, each certificate linked to a specific batch identifier.